Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Oncology Report

• Publication date

  2012-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/or.2012.2045PMID 22993103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.

  2010cited by this paper
• Vascular endothelial growth factor--a positive and negative regulator of tumor growth.

  2010cited by this paper
• VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration.

  2010cited by this paper
• Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells.

  2010cited by this paper
• High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia.

  2010cited by this paper
• VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis

  2010cited by this paper
• CD147 and VEGF co-expression predicts prognosis in patients with acute myeloid leukemia.

  2010cited by this paper
• Vitamin E and rutin synergistically inhibit expression of vascular endothelial growth factor through down-regulation of binding activity of activator protein-1 in human promyelocytic leukemia (HL-60) cells.

  2010cited by this paper
• Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL).

  2010cited by this paper
• Inhibition of angiogenesis by the BTB domain of promyelocytic leukemia zinc finger protein.

  2010cited by this paper
• An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.

  2010cited by this paper
• Suppression of Vascular Endothelial Growth Factor (VEGF) Expression by Targeting the Bcr-Abl Oncogene and Protein Tyrosine Kinase Activity in Bcr-Abl-positive Leukaemia Cells

  2009cited by this paper
• Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB.

  2009cited by this paper
• Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression

  2009cited by this paper
• Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia.

  2009cited by this paper
• Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells.

  2009cited by this paper
• Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

  2009cited by this paper
• Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome

  2009cited by this paper
• Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands

  2009cited by this paper
• Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells

  2009cited by this paper
• Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia

  2008cited by this paper
• Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.

  2008cited by this paper
• Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• VEGF-targeted therapy: mechanisms of anti-tumour activity

  2008cited by this paper
• Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.

  2008cited by this paper
• Dysregulated angiogenesis in B-chronic lymphocytic leukemia: Morphologic, immunohistochemical, and flow cytometric evidence

  2008cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia

  2007cited by this paper
• Autocrine VEGF loops, signaling pathways, and acute leukemia regulation

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.

  2007cited by this paper
• Angiogenesis and antiangiogenic therapy in hematologic malignancies.

  2007cited by this paper
• The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII.

  2007cited by this paper
• Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia.

  2007cited by this paper
• Unbalanced alternative splicing and its significance in cancer

  2006cited by this paper
• Targeting Signal‐Transducer‐and‐Activator‐of‐Transcription‐3 for Prevention and Therapy of Cancer

  2006cited by this paper
• Targeting NF-kappaB in hematologic malignancies.

  2006cited by this paper
• Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells.

  2006cited by this paper
• The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma

  2006cited by this paper
• Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Targeting NF-κB in hematologic malignancies

  2006cited by this paper
• Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma

  2006cited by this paper
• Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.

  2005cited by this paper
• AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

  2005cited by this paper
• Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy

  2005cited by this paper
• Anti-angiogenic strategies for cancer therapy (Review).

  2005cited by this paper
• Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells.

  2005cited by this paper
• Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

  2005cited by this paper
• Properties of thalidomide and its analogues: Implications for anticancer therapy

  2005cited by this paper
• Targeting primary human leukaemia cells with RNA interference: Bcr‐Abl targeting inhibits myeloid progenitor self‐renewal in chronic myeloid leukaemia cells

  2005cited by this paper
• Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia.

  2005cited by this paper
• VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.

  2004cited by this paper
• Cyclooxygenase-2 Induces EP1- and HER-2/Neu-Dependent Vascular Endothelial Growth Factor-C Up-Regulation

  2004cited by this paper
• Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells.

  2004cited by this paper
• Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation.

  2004cited by this paper
• Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.

  2003cited by this paper
• Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice.

  2003cited by this paper
• Fundamental concepts of the angiogenic process.

  2003cited by this paper
• Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.

  2003cited by this paper
• Placental growth factor and its receptor, vascular endothelial growth factor receptor‐1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

  2003cited by this paper
• Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

  2003cited by this paper
• Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

  2002cited by this paper
• Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3.

  2002cited by this paper
• New Vessel Formation and Aberrant VEGF/VEGFR Signaling in Acute Leukemia: Does it Matter?

  2002cited by this paper
• PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

  2002cited by this paper
• B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

  2002cited by this paper
• Efficacy and safety of thalidomide in patients with acute myeloid leukemia.

  2002cited by this paper
• In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo.

  2002cited by this paper
• Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

  2002cited by this paper
• Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

  2002cited by this paper
• Clinical Importance of Serum Vascular Endothelial and Basic Fibroblast Growth Factors in Children with Acute Lymphoblastic Leukemia

  2001cited by this paper
• c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells.

  2001cited by this paper
• Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.

  2001cited by this paper
• Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.

  2001cited by this paper
• Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

  2001cited by this paper
• Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells

  2001cited by this paper
• Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system

  2001cited by this paper
• High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.

  2001cited by this paper
• Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

  2001cited by this paper
• Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion.

  2001cited by this paper
• Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis.

  2001cited by this paper
• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

  2001cited by this paper
• The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells.

  2001cited by this paper
• Stress-activated Protein Kinases (JNK and p38/HOG) Are Essential for Vascular Endothelial Growth Factor mRNA Stability*

  2000cited by this paper
• Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.

  2000cited by this paper
• Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

  2000cited by this paper
• Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.

  2000cited by this paper
• In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells.

  2000cited by this paper
• STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.

  2000cited by this paper
• Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis.

  2000cited by this paper

• VEGF Inhibitors in Hematologic Cancers and Hypertension/Cardiac Effects.

  2026cites this paper
• The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance.

  2026cites this paper
• Deciphering Multitarget Mechanisms of Cardiac Glycosides in Acute Myeloid Leukemia Using a Network Pharmacology and Molecular Docking

  2026influential citation
• MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

  2026cites this paper
• Update Prognostic Potency of Vascular Endothelial Growth Factor‐A in the Acute Lymphoblastic Leukemia Landscape: A Meta‐Analysis

  2025cites this paper
• Semi-Synthetic Derivatives from a Lupane-Type Triterpene Isolated from Phoradendron wattii with Anti-Leukemia Activity

  2025cites this paper
• Thymus-Brain Connections in T-Cell Acute Lymphoblastic Leukemia

  2024cites this paper
• Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient

  2024cites this paper
• Expanding Beyond Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia: A Pathway-Based Stratification of Patients for Precision Oncology

  2024cites this paper
• 1,3-Disubstituted Thiourea Derivatives: Promising Candidates for Medicinal Applications with Enhanced Cytotoxic Effects on Cancer Cells.

  2024cites this paper
• Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer

  2024cites this paper
• Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions.

  2024cites this paper
• The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity

  2024cites this paper
• Novel circular RNAs of the apoptosis‐related BAX and BCL2L12 genes identified in a chronic lymphocytic leukemia cell line using nanopore sequencing

  2023cites this paper
• The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways

  2023cites this paper
• Molecular Targeting Therapy for Advanced Gastric Carcinoma

  2023cites this paper
• Comprehensive analysis of the oncogenic roles of vascular endothelial growth factors and their receptors in stomach adenocarcinoma

  2023cites this paper
• Synthesis and Molecular Docking of Some Novel 3-Thiazolyl-Coumarins as Inhibitors of VEGFR-2 Kinase

  2023cites this paper
• Targeting metabolism: A potential strategy for hematological cancer therapy

  2022cites this paper
• Lupane Triterpene Derivatives Improve Antiproliferative Effect on Leukemia Cells through Apoptosis Induction

  2022cites this paper
• Apoptotic and Cell Cycle Effects of Triterpenes Isolated from Phoradendron wattii on Leukemia Cell Lines

  2022cites this paper
• Original Genomic mutation characteristics and prognosis of biliary tract cancer

  2022cites this paper
• Genomic mutation characteristics and prognosis of biliary tract cancer.

  2022cites this paper
• The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia.

  2022cites this paper
• CSF-1 maintains pathogenic but not homeostatic myeloid cells in the central nervous system during autoimmune neuroinflammation

  2022cites this paper
• Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy

  2021cites this paper
• The Tyrosine Kinase-Driven Networks of Novel Long Non-coding RNAs and Their Molecular Targets in Myeloproliferative Neoplasms

  2021cites this paper
• Apatinib Enhances Chemosensitivity of FLT3-ITD Mutations acute Myeloid Leukemia Cells to Homoharringtonine Via VEGFR2 Pathway

  2021cites this paper
• Identification of MiR-93-5p Targeted Pathogenic Markers in Acute Myeloid Leukemia through Integrative Bioinformatics Analysis and Clinical Validation

  2021cites this paper
• A narrative review of central nervous system involvement in acute leukemias

  2021cites this paper
• Gastrointestinal Toxicities of Targeted Therapy

  2020cites this paper
• N-Ethyl-n-Nitrosourea Induced Leukaemia in a Mouse Model through Upregulation of Vascular Endothelial Growth Factor and Evading Apoptosis

  2020cites this paper
• Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors

  2020cites this paper
• Targeting CSF-1 ameliorates experimental autoimmune encephalomyelitis by depleting inflammatory monocytes and microglia in the central nervous system without affecting quiescent microglia

  2020cites this paper
• Modulation of cytokine production by monocytes and developing‐dendritic cells under the influence of leukemia and lymphoma cell products

  2020cites this paper
• Hypoxia-Inducible Factor 1-Α (HIF1α) and Vascular Endothelial Growth Factor-A (VEGF-A) Expression in De Novo AML Patients

  2019cites this paper
• Does Surgical Treatment Affect Serum Levels of Vascular Endothelial Growth Factors (VEGF) in Orofacial Tumours?

  2019cites this paper
• Thiazole in the targeted anticancer drug discovery.

  2019cites this paper
• Angiogenic and FLT 3 Receptors Expression in Acute Lymphoblastic Leukemia in Pediatric Age Group

  2019cites this paper
• Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome

  2018cites this paper
• Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells

  2018influential citation
• The Effect of Placenta Growth Factor Knockdown on hsa-miR-22-3p, hsa-let-7b-3p, hsa-miR-451b, and hsa-mir-4290 Expressions in MKN-45- derived Gastric Cancer Stem-like Cells

  2018cites this paper
• Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.

  2018cites this paper
• Identification and functional characterisation of gene fusions in human cancer cell lines

  2018cites this paper
• Synthesis, characterization and cytotoxicity studies of 1,2,3-triazoles and 1,2,4-triazolo [1,5-a] pyrimidines in human breast cancer cells.

  2018cites this paper
• Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine

  2018cites this paper
• Response of Myeloid Leukemia Cells to Luteolin is Modulated by Differentially Expressed Pituitary Tumor-Transforming Gene 1 (PTTG1) Oncoprotein

  2018cites this paper
• Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications

  2017cites this paper
• miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism.

  2017cites this paper
• Identification of specifically activated angiogenic molecules in HMGB-1-induced angiogenesis

  2017cites this paper
• MYELOID NEOPLASIA miR-125 b promotes MLL-AF 9 – driven murine acute myeloid leukemia involving a VEGFA-mediated non – cell-intrinsic mechanism

  2017cites this paper
• High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia

  2017cites this paper
• A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy

  2017cites this paper
• Anti-Vascular Endothelial Growth Factor Effects of Sorafenib and Arsenic Trioxide in Acute Myeloid Leukemia Cell Lines

  2017cites this paper
• The Endothelial Nitric Oxide Synthase Gene Variants as a Risk Factor for Chronic Lymphocytic Leukemia

  2017cites this paper
• Development of a robust reporter-based assay for the bioactivity determination of anti-VEGF therapeutic antibodies.

  2016cites this paper
• Perturbed Calcineurin-NFAT Signaling Is Associated with the Development of Alzheimer's Disease.

  2016cites this paper
• Pretreatment of Cardiac Stem Cells With Exosomes Derived From Mesenchymal Stem Cells Enhances Myocardial Repair

  2016cites this paper
• Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production

  2016cites this paper
• Endocrine regulation of maternal vascular adaptations to pregnancy

  2016cites this paper
• Functionality determination and characterization of an angiogenesis-inhibiting fusion protein

  2016cites this paper
• Profiling of microRNAs in AML cells following overexpression or silencing of the VEGF gene

  2016cites this paper
• The progress of angiogenic factors in the development of leukemias.

  2016cites this paper
• Gene expression profiling for targeted cancer treatment

  2015cites this paper
• Lymphoproliferative neoplasms and renal cell carcinoma of clear cell type--Where is the link?

  2015cites this paper
• Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

  2015cites this paper
• Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia.

  2015cites this paper
• Up-regulation of VEGF and its receptor in refractory leukemia cells.

  2015cites this paper
• Role of Plasma Membrane Caveolae/Lipid Rafts in VEGF-Induced Redox Signaling in Human Leukemia Cells

  2014cites this paper
• CD95 signaling in cancer treatment.

  2014cites this paper
• Альтернативное кровоснабжение в костном мозге при онкогематологических заболеваниях

  2014cites this paper
• Current protein-based anti-angiogenic therapeutics.

  2014cites this paper
• Exploration for the multi-effect of cardamom in's resistance to multiple myeloma.

  2014cites this paper
• Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

  2013cites this paper